Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Autologous genetically modified AFPᶜ³³²T cells
ADP-A2AFP · 1 trial · 2 indications
Determine if treatment with autologous genetically modified T cells, (AFPᶜ³³²T) is safe and tolerable through assessment of DLTs, AEs, including SAEs; laboratory assessments including chemistry, hematology, coagulation, cardiac assessments including ECG, and cardiac Troponin
| Arm | Type | Description |
|---|---|---|
| Autologous genetically modified AFPᶜ³³²T cells | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Autologous genetically modified AFPᶜ³³²T cells | GENETIC | Infusion of autologous genetically modified AFPᶜ³³²T cells |
Key Inclusion Criteria: 1. Subject is ≥ 18 years and ≤ 75 years of age and has voluntarily agreed to participate by giving written informed consent in accordance with ICH GCP Guidelines and applicable local regulations. 2. Histologically confirmed HCC, not amenable to transplant, resection. Subject...
ADP-A2AFP is an investigational cell therapy being studied for hepatocellular cancer, including AFP-expressing tumors. It is being evaluated in patients with advanced disease. It is not approved for commercial use and remains in clinical development.
ADP-A2AFP is being developed by Adaptimmune Therapeutics PLC, which trades on the Nasdaq under the ticker ADAP. The company is the sponsor of the clinical program evaluating this autologous genetically modified T cell therapy in advanced liver cancer.
ADP-A2AFP is in Phase 1 clinical development. The program has one active trial that is no longer recruiting participants. No Phase 2 or Phase 3 studies and no completed trials have been recorded for this asset.
ADP-A2AFP is being evaluated in the Phase 1 trial NCT03132792, titled AFPᶜ³³²T in Advanced HCC. The study is active but not recruiting, with an enrollment of 45 patients across the United States, France, Spain, and the United Kingdom.
Yes. ADP-A2AFP is also known as autologous genetically modified AFPᶜ³³²T cells. The two names refer to the same investigational cell therapy developed by Adaptimmune Therapeutics for AFP-expressing hepatocellular cancer.
No. ADP-A2AFP is an investigational gene therapy still in Phase 1 clinical development and has not been approved by the FDA. It is available only to participants enrolled in its clinical trial.